Bristol-Myers Squibb myeloma drug flunks Phase III combination trial in first-line disease
The trial tested Empliciti with Revlimid and dexamethasone in newly diagnosed patients ineligible for bone marrow transplant. Although approved in relapsed/refractory disease, Empliciti has not kept pace on the market with other myeloma drugs.